

**From:** Smith, Michael (CBER)

**Sent:** Monday, August 16, 2021 10:38 AM

**To:** Harkins Tull, Elisa <Elisa.HarkinsTull@pfizer.com>

**Cc:** Naik, Ramachandra <Ramachandra.Naik@fda.hhs.gov>; Gottschalk, Laura <Laura.Gottschalk@fda.hhs.gov>; Aghajani Memar, Neda <Neda.AghajaniMemar@pfizer.com>; Devlin, Carmel M <Carmel.Devlin@pfizer.com>; Rohlfing, Paul <Paul.Rohlfing@pfizer.com>

**Subject:** STN 125742.0: IR RE diluent suppliers

Elisa,

The review team has the below information request for you regarding your diluent suppliers:

Due to the Warning Letter (reference WL 320-20-31 issued 03/25/2020) and Official Action Indicated status of Pfizer Healthcare India Pvt. Ltd. (FEI# 3008316085), the Agency will not approve the diluent supplied from that manufacturer as part of your BLA. Please acknowledge this notification and remove all references to this supplier from the BLA, including in the recently added Diluent Manufacturers table.

Regards,

Mike

- Please confirm receipt of this e-mail and let us know if you have any questions.

**Mike Smith, Ph.D.**  
**Captain, USPHS**

**Senior Regulatory Review Officer**  
**Food and Drug Administration**  
**Center for Biologics Evaluation & Research**  
**Office of Vaccines Research & Review**  
**Division of Vaccines and Related Products Applications**  
Tel: 301-796-2640

[michael.smith2@fda.hhs.gov](mailto:michael.smith2@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.